학술논문
667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Document Type
Abstract
Author
Source
In Annals of Oncology October 2023 34 Supplement 2:S469-S469
Subject
Language
ISSN
0923-7534